Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 22323773)

1.

Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles.

Gedda L, Fondell A, Lundqvist H, Park JW, Edwards K.

J Nucl Med. 2012 Mar;53(3):480-7. doi: 10.2967/jnumed.111.096891. Epub 2012 Feb 8.

2.

Nuclisome--targeting the tumor cell nucleus.

Gedda L, Edwards K.

Tumour Biol. 2012 Jun;33(3):661-7. doi: 10.1007/s13277-012-0341-3.

PMID:
22302484
3.

In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an (125)I-labelled DNA-intercalator.

Fondell A, Edwards K, Unga J, Kullberg E, Park JW, Gedda L.

J Drug Target. 2011 Nov;19(9):846-55. doi: 10.3109/1061186X.2011.589436. Epub 2011 Jun 22.

PMID:
21692679
4.

Nuclisome: a novel concept for radionuclide therapy using targeting liposomes.

Fondell A, Edwards K, Ickenstein LM, Sjöberg S, Carlsson J, Gedda L.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):114-23. doi: 10.1007/s00259-009-1225-7. Epub .

PMID:
19662408
5.

The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.

Tolmachev V, Wållberg H, Andersson K, Wennborg A, Lundqvist H, Orlova A.

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1460-8. doi: 10.1007/s00259-009-1134-9. Epub 2009 May 9.

PMID:
19430786
7.

Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons.

Mattes MJ, Goldenberg DM.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1249-58. doi: 10.1007/s00259-008-0731-3. Epub 2008 Feb 12.

PMID:
18265976
8.

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V.

J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16.

9.

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.

J Nucl Med. 2005 Nov;46(11):1907-15.

10.

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.

Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM.

J Nucl Med. 2010 Jul;51(7):1084-91. doi: 10.2967/jnumed.109.072389. Epub 2010 Jun 16.

11.

Role of lipid-soluble complexes in targeted tumor therapy.

Thakur ML, Coss R, Howell R, Vassileva-Belnikolovska D, Liu J, Rao SP, Spana G, Wachsberger P, Leeper DL.

J Nucl Med. 2003 Aug;44(8):1293-300.

12.

(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Orlova A, Tran TA, Ekblad T, Karlström AE, Tolmachev V.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):260-9. doi: 10.1007/s00259-009-1268-9. Epub 2009 Sep 22.

PMID:
19771426
13.

Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.

Abbas N, Bruland ØS, Brevik EM, Dahle J.

Nucl Med Commun. 2012 Aug;33(8):838-47. doi: 10.1097/MNM.0b013e328354df7c.

PMID:
22643311
14.

Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.

Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Maecke HR, Forssell-Aronsson E.

J Nucl Med. 2004 Sep;45(9):1542-8.

15.

Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.

Orlova A, Tran T, Widström C, Engfeldt T, Eriksson Karlström A, Tolmachev V.

Int J Mol Med. 2007 Sep;20(3):397-404.

PMID:
17671747
17.

Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE.

Bioconjug Chem. 2000 May-Jun;11(3):327-34.

PMID:
10821648
18.

Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.

Steffen AC, Orlova A, Wikman M, Nilsson FY, Ståhl S, Adams GP, Tolmachev V, Carlsson J.

Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):631-8. Epub 2006 Mar 15.

PMID:
16538504
19.

Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.

Tsai CC, Chang CH, Chen LC, Chang YJ, Lan KL, Wu YH, Hsu CW, Liu IH, Ho CL, Lee WC, Ni HC, Chang TJ, Ting G, Lee TW.

Int J Nanomedicine. 2011;6:2607-19. doi: 10.2147/IJN.S23834. Epub 2011 Oct 26.

20.

Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells.

Hoang B, Reilly RM, Allen C.

Biomacromolecules. 2012 Feb 13;13(2):455-65. doi: 10.1021/bm201479t. Epub 2012 Jan 17.

PMID:
22191486
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk